MondoTwin Pharma · Business Development & Licensing
De-risked assets.
Ready for your signature.
We scout the opportunities your pipeline needs, backed by clinical evidence. Then we secure the asset and bring you the agreement, ready to sign.

How it works
From your mandate
to a signed agreement.
- 01
Define the mandate.
Indication, stage, modality, territory and priorities: what your next programme needs to be.
- 02
Scout de-risked opportunities.
The Twin’s agents read the registered trials, the drugs and the literature in your search space. We focus on assets supported by clinical evidence, each claim traced to its primary source.
- 03
Secure the asset.
Through our community of researchers, rights holders and specialists, we reach the rights holder, clarify ownership and negotiate the terms.
- 04
Deliver the agreement.
You receive the asset with its evidence and a negotiated licence. What is left is your signature.

What we examine
Evidence first.
Then rights and development.
- 01
Clinical evidence.
Human data first: study results, the primary record and what they show for the indication.
- 02
Therapeutic fit.
Indication, patient population, unmet need and your priorities.
- 03
Rights and availability.
Ownership, territories, patents, other protections and the rights holder’s willingness to engage.
- 04
The next development step.
The work, specialists and partners needed for the next decision.
The commercial structure
Value follows
the programme.
A defined mandate
Scoped search and Business Development work around your priorities.
A programme assessment
Scientific, rights and development questions assessed with the relevant specialists.
A licensing agreement
Upfront consideration, milestones and royalties where agreed. Assessment costs may be credited against the upfront payment under the negotiated terms.

The first AI-native department
Business Development first.
More departments next.
One department at a time,
each proven before the next.
Business Development is the first AI-native department of the Pharma Twin. Further departments are added as each one proves its value.
It starts from MondoBiotech’s rare-disease search-and-license model, revived with AI across the public clinical evidence.
Tell us what your pipeline needs.
Start with a non-confidential mandate.
